This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.
Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.

 

This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.

Are you a healthcare professional?

Speaker - Michael Heneka
Michael
Heneka
The Luxembourg Centre for Systems Biomedicine, Luxembourg, Luxembourg

Professor Michael Heneka is a board-certified neurologist and clinician-scientist with more than 25 years of experience in studying neurodegenerative diseases at experimental, preclinical and clinical levels. 

 

He has a long-standing interest in immunology and neuroscience. While the main focus of his work is related to dementia and Alzheimer’s disease, Professor Heneka has also been researching amyotrophic lateral sclerosis and Parkinson’s disease.

 

At the clinical level, he established a neurodegenerative outpatient unit at both the University of Münster, Münster and the University of Bonn, Bonn, Germany. From 2016 to 2021, he led the department of Neurodegenerative Disease and Geriatric Psychiatry in Bonn. 

 

Since January 2022, he is the Director of the Luxembourg Centre for Systems Biomedicine (LCSB) at the University of Luxembourg and Principal Investigator in the Neuroinflammation group (Heneka Lab).

properties.alt

Emma Lane

Cardiff University, Cardiff, Wales, UK


Dr Emma Lane is a Reader in Neuropharmacology at the School of Pharmacy and Pharmaceutical Sciences at Cardiff University, Cardiff, Wales, UK.   

 

After completing a PhD at King’s College London, London, UK and a postdoctoral research position at Lund University, Lund, Sweden with Patrik Brundin and Angela Cenci, she moved to Cardiff University to work with Steve Dunnett and Anne Rosser in the Brain Repair Group. Dr Lane established her own independent group within the School of Pharmacy and Pharmaceutical Sciences in 2009, focusing on modelling and understanding the side effects of current and novel therapeutic interventions for Parkinson’s disease in rodent models.  

 

In particular, her work is providing an evidence base for optimising cell and gene therapies alongside concurrent pharmacotherapy. With a long-held interest in public engagement and public involvement and as the lead for the BRAIN Involve PPI group, Dr Lane leads the LEARN (Listening to the Experiences of pARticipants on Neurosurgical trials) study group. This team is implementing a series of mixed-methods studies to collate the participant experience of clinical trials of new complex interventions for neurodegenerative diseases. This knowledge will be used to inform the design of future trials, and delivery of therapies, to improve information for both participants and their families, as well as processes and outcome measures. This is being done collaboratively with the participants, those who hope to benefit most from these new innovations in treatment. 


Read full bio
properties.alt

Gesine Paul-Visse

Lund University, Lund, Sweden


Professor Gesine Paul-Visse is a senior consultant neurologist and adjunct professor of Neurology at Lund University, Lund and Skåne University Hospital, Scania, Sweden. 

 

She trained at the Charité – Universitätsmedizin Berlin, Germany, the United Medical and Dental Schools of Guy’s and St Thomas’ Hospitals (UMDS), London, UK and at the University of St Andrews, St Andrews, Scotland, UK. Attracted by Lund as a worldwide pioneering centre for neurotransplantation, Professor Paul-Visse joined the laboratory of Professor Patrik Brundin at Lund University in 2001 to work with cell therapies and neuroregeneration. Since 2011, she has led a preclinical research group “Translational Neurology” at Lund University, with a focus on understanding mechanisms of neurodegenerative disorders and identifying novel targets for neuroprotection. 

 

Professor Paul-Visse works with patients with all neurological disorders but has a specialised profile in Parkinson’s disease. As such, she was head of the clinical movement disorder team (2016–2019) and serves on the board of the Swedish Movement Disorder Society (Swemodis), the Swedish Parkinson Academy, the Swedish Basal Ganglia Society (SWEBAGS), the Swedish Parkinson Registry (SWEPAR) and the Network of European CNS Transplantation and Restoration (NECTAR). She has also contributed to the national guidelines for Parkinson’s disease.

 

For more than a decade, Professor Paul-Visse has been a clinical investigator (or coordinating principal investigator) in several frontline clinical phase 1/2a trials that address the neurorestorative effect of growth factors (intracerebroventricular administration of platelet-derived growth factor and intracerebral administration of cerebral dopaminergic neurotrophic factor) in Parkinson’s disease. 

 

She has also gained ample experience in cell transplantation by being a clinical investigator in the TransEuro trial, in which dopaminergic progenitors from foetal tissue were grafted into the putamen of patients with Parkinson’s disease using a similar stereotactic approach to the one planned for the STEM-PD trial. 


Read full bio